Icotrokinra Wins FDA as the First Oral IL-23 Inhibitor and Beats Deucravacitinib Head-to-Head

A drug that breaks the injection ceiling of psoriasis care just won FDA approval. Johnson & Johnson’s icotrokinra became the first oral IL-23 inhibitor in 2026. Until now, every IL-23 inhibitor was injectable (ustekinumab, guselkumab, risankizumab). Icotrokinra is a targeted oral peptide engineered to block IL-23 signaling while delivered as a daily pill.

The pivotal data come from the ICONIC head-to-head trial, which compared icotrokinra against deucravacitinib (Sotyktu, BMS’s oral TYK2 inhibitor) directly. At week 16, icotrokinra achieved meaningfully higher PASI 75 and PASI 90 rates than deucravacitinib. PASI 75 reached approximately 70%, with sPGA 0/1 clear-or-almost-clear rates trending the same direction. All major endpoints were statistically superior to placebo. Efficacy held through week 60.

The molecular circuit of psoriasis runs IL-23 → Th17 differentiation → IL-17 → keratinocyte hyperproliferation → thick scaling and erythema. Blocking IL-23 at the upstream node weakens the entire chain. Injectable IL-23 inhibitors (Skyrizi/risankizumab, Tremfya/guselkumab) have shown the strongest PASI 90–100% achievement. Icotrokinra delivers the same target through the oral route for the first time.

Deucravacitinib (Sotyktu), a selective TYK2 inhibitor approved in 2022 as the first oral psoriasis drug, came with efficacy ceilings in some patients and a boxed warning related to opportunistic infection in immunodeficient populations. Icotrokinra’s direct superiority signals that a new first-line oral option for psoriasis is emerging.

The clinical weight for women has three dimensions. First, women make up about 50% of psoriasis cases, but female-skewed phenotypes exist (palmoplantar psoriasis, scalp line involvement, nail psoriasis). Second, injectable biologics (especially IgG1 formats) carry placental transfer concerns in late pregnancy, limiting use in women planning pregnancy. Oral formats have different pharmacokinetics due to smaller molecular weight, and accumulating pregnancy data may produce clearer guidelines. Third, in Korea over 80% of psoriasis patients remain on first-line topical or phototherapy, with low transition rates to injectable biologics. Oral options can close that gap.

The side effect profile tracks placebo. Mild headache, sore throat, nasopharyngitis. Approval came without a boxed warning — a meaningful contrast with deucravacitinib’s box.

Dosing is once daily oral tablet (specific dose per prescribing information). Taken with or without food. Effect begins at weeks 4–8 and stabilizes by week 16. For patients reaching PASI 90 or sPGA 0/1, future studies will examine extended-interval or step-down protocols beyond week 24.

Pricing-wise, market entry into Korea is expected 12–18 months after the US release. Specialty disease cost reimbursement, insurance status, and prescribing conditions will be set at launch. Korean dermatology gains a first-line oral option for moderate-to-severe psoriasis.

Given that psoriasis is a chronic immune-mediated condition requiring lifelong management, expanding therapeutic choice carries real patient meaning. Patients avoiding injections, those hesitant about biologics due to immunosuppression concerns, and women with reproductive plans gain a new first-line option in icotrokinra.